Overview
Frank Scheuermeyer-Xavier practices in Vancouver, Canada. Mr. Scheuermeyer-Xavier is rated as an Experienced expert by MediFind in the treatment of Anaphylaxis. His top areas of expertise are Cardiac Arrest, Atrial Fibrillation, Acute Coronary Syndrome, and Ventricular Fibrillation.
His clinical research consists of co-authoring 180 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Anaphylaxis.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Cardiac ArrestMr. Scheuermeyer-Xavier isDistinguished. Learn about Cardiac Arrest.
- Advanced
- Acute Coronary SyndromeMr. Scheuermeyer-Xavier isAdvanced. Learn about Acute Coronary Syndrome.
- Atrial FibrillationMr. Scheuermeyer-Xavier isAdvanced. Learn about Atrial Fibrillation.
- Experienced
- AnaphylaxisMr. Scheuermeyer-Xavier isExperienced. Learn about Anaphylaxis.
- AnginaMr. Scheuermeyer-Xavier isExperienced. Learn about Angina.
- CellulitisMr. Scheuermeyer-Xavier isExperienced. Learn about Cellulitis.
- ConcussionMr. Scheuermeyer-Xavier isExperienced. Learn about Concussion.
- Coronary Heart DiseaseMr. Scheuermeyer-Xavier isExperienced. Learn about Coronary Heart Disease.
- COVID-19Mr. Scheuermeyer-Xavier isExperienced. Learn about COVID-19.